Shares of JELD-WEN Holding, Inc. (NYSE:JELD – Get Free Report) have earned an average recommendation of “Hold” from the eleven brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $17.30.
Several research firms recently issued reports on JELD. Barclays decreased their price target on JELD-WEN from $15.00 to $13.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Jefferies Financial Group increased their price objective on shares of JELD-WEN from $15.00 to $17.00 and gave the company a “hold” rating in a report on Wednesday, October 9th. Loop Capital lowered their target price on shares of JELD-WEN from $17.00 to $16.00 and set a “hold” rating for the company in a report on Friday, July 19th. Royal Bank of Canada reissued an “underperform” rating and issued a $13.00 price target on shares of JELD-WEN in a research note on Wednesday, August 7th. Finally, The Goldman Sachs Group upped their price objective on JELD-WEN from $15.00 to $17.00 and gave the company a “neutral” rating in a report on Tuesday, October 8th.
Check Out Our Latest Analysis on JELD-WEN
JELD-WEN Stock Performance
JELD-WEN (NYSE:JELD – Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.11. The firm had revenue of $986.00 million during the quarter, compared to analysts’ expectations of $1 billion. JELD-WEN had a negative net margin of 0.92% and a positive return on equity of 14.32%. JELD-WEN’s revenue was down 12.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.44 EPS. On average, research analysts anticipate that JELD-WEN will post 1.29 earnings per share for the current fiscal year.
Institutional Trading of JELD-WEN
Institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its stake in JELD-WEN by 790.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,165 shares of the company’s stock valued at $46,000 after buying an additional 1,922 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in JELD-WEN by 26.6% during the first quarter. BNP Paribas Financial Markets now owns 52,153 shares of the company’s stock worth $1,107,000 after acquiring an additional 10,943 shares in the last quarter. Empowered Funds LLC boosted its position in JELD-WEN by 8.2% during the first quarter. Empowered Funds LLC now owns 359,817 shares of the company’s stock valued at $7,639,000 after purchasing an additional 27,234 shares during the last quarter. Russell Investments Group Ltd. grew its stake in JELD-WEN by 12.5% in the first quarter. Russell Investments Group Ltd. now owns 111,135 shares of the company’s stock valued at $2,359,000 after purchasing an additional 12,330 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in JELD-WEN by 8.5% during the first quarter. ProShare Advisors LLC now owns 15,305 shares of the company’s stock worth $325,000 after buying an additional 1,205 shares during the last quarter. 95.04% of the stock is currently owned by institutional investors.
JELD-WEN Company Profile
JELD-WEN Holding, Inc designs, manufactures, and sells wood, metal, and composite materials doors, windows, and related building products in North America and Europe. The company offers a line of residential interior and exterior door products, including patio doors, and folding or sliding wall systems; non-residential doors; stile and rail doors; and wood, vinyl, and wood composite windows.
Recommended Stories
- Five stocks we like better than JELD-WEN
- What is MarketRank™? How to Use it
- Intel: Is Now the Time to Be Brave?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Upcoming IPO Stock Lockup Period, Explained
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for JELD-WEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JELD-WEN and related companies with MarketBeat.com's FREE daily email newsletter.